Objective: The purpose of this study was to investigate the effectiveness of intratympanic dexamethasone injection as a protection agent against cisplatin-induced ototoxicity.
Study Design And Setting: The four groups of guinea pigs were injected as follows: 1) cisplatin, 2) intratympanic dexamethasone, 3) cisplatin following intratympanic dexamethasone, and 4) cisplatin after intratympanic saline. Before and 3 days following injections, the ototoxic effect was measured with distortion product otoacoustic emissions (DPOAEs).
Results: The DPOAEs amplitudes and signal-to-noise ratio (SNR) values at 1 to 6 kHz frequencies for group 1 animals after injections significantly decreased over those before injections (P < 0.05). In group 2, there were no significant differences in DPOAE amplitude and SNR values between before and after intratympanic dexamethasone injections (P > 0.05). Considering group 3, there were also no significant differences in DPOAEs amplitudes and SNR values before and after of dexamethasone and cisplatin injections (P > 0.05).
Conclusions: Intratympanic dexamethasone injection did not cause any ototoxic effect; in contrast, it might have a significant protective effect after cisplatin injection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.otohns.2007.05.068 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison between intratympanic injection of dexamethasone and methylprednisolone in idiopathic sudden sensorineural hearing loss: A randomized clinical trial.
Laryngoscope Investig Otolaryngol
December 2024
Hearing Disorders Research Center, Loghman Hakim Hospital Shahid Beheshti University of Medical Sciences Tehran Iran.
Objective: To compare the hearing outcomes of patients with idiopathic sudden sensorineural hearing loss after intratympanic (IT) injection of methylprednisolone and dexamethasone.
Study Design: Randomized case-controlled clinical trial.
Methods: Seventy-five patients diagnosed with idiopathic sensorineural hearing loss were randomly divided into two groups based on therapy.
Effect of Intratympanic Dexamethasone on Bell's palsy: A Clinical Trial.
Iran J Otorhinolaryngol
January 2024
Otorhinolaryngology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Introduction: The main objective of this study is to examine the hypothesis that intratympanic corticosteroids can benefit the treatment of Bell's palsy and shorten the period needed for recovery.
Materials And Methods: This study was conducted prospectively using double-blind clinical trials. A total of 321 patients with acute unilateral facial paralysis were included in the survey, with 144 patients excluded due to exclusion criteria and 177 patients included.
Plasma Concentration as a Proxy for Perilymph Drug Levels: Preclinical and Clinical Dexamethasone Measures with a Long-Acting Formulation for Precise Delivery to the Round Window Membrane.
Otol Neurotol
January 2025
Turner Scientific, Inc., Jacksonville, Illinois, USA.
Objective: To use animal pharmacokinetic data and FluidSIM modeling to estimate human dexamethasone perilymph concentrations from plasma concentration measurements over time following a single intratympanic administration of SPT-2101.
Study Design: Perilymph and plasma dexamethasone concentrations were measured in guinea pigs and African green monkeys over 3 to 6 weeks post-intratympanic administration of SPT-2101. Plasma concentrations of dexamethasone were measured in Ménière's disease patients post-intratympanic administration of SPT-2101.
Programmable NIR Responsive Nanocomposite Enables Noninvasive Intratympanic Delivery of Dexamethasone to Reverse Cisplatin Induced Hearing Loss.
Adv Sci (Weinh)
November 2024
Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University, Turku, 20520, Finland.
Local intratympanic drug delivery to the inner ear possesses significant otological clinical promise as cisplatin-induced hearing loss (CIHL) therapy, inducing significantly less side effects than systemic drug delivery. However, the multiple detoured barriers, round window membrane (RWM) and poorly controlled drug release hinder successful non-invasive drug delivery through intratympanic administration (IT). Here, a novel near-infrared (NIR) responsive nanocomposite functionalized with saponin, denoted gold nanorod@dexamethasone-mesoporous silica-saponin (AuNR@DEX-MS-saponin, NPs/DEX), is developed to enhance RWM permeation and to control the drug release spatiotemporally.
View Article and Find Full Text PDFImproved intracochlear biopolymeric drug delivery system: an study.
Acta Otolaryngol
December 2024
Department of Otolaryngology - Head and Neck Surgery, University of Miami Ear Institute, University of Miami, Miller School of Medicine, Miami, FL, USA.
Background: The delivery of drugs into the inner ear is a challenging field of study due to the complex cochlear anatomy and physiology. The creation of an intracochlear device that allows for short- and long-term intracochlear delivery of the drugs with a minimal invasive technology is needed to prevent or treat conditions that can potentially prevent the development of permanent hearing loss.
Aim: This study intends to test the efficacy of DXM-infused PLGA microneedles created in our laboratory in an animal model of acute ototoxic injury.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!